Mtech Access explore the strategic and tactical challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.
Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.
Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.
Rob, Regina and Calum discuss:
- Current and future market events and trends for rare disease products across Europe
- Clinical evidence development, including tactical challenges around evidence generation and how to address these
- Building the health economic case, including key principles and tactical nuances for health economic modelling in rare and orphan disease
Learn more and request a copy of the slides at: [ Ссылка ]
